BioLargo Files 8-K for Regulation FD Disclosure, Financial Exhibits

Ticker: BLGO · Form: 8-K · Filed: Jan 10, 2024 · CIK: 880242

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, financial-statements, corporate-governance

TL;DR

**BLGO just dropped an 8-K with new disclosures, check for key updates!**

AI Summary

BioLargo, Inc. filed an 8-K on January 10, 2024, to disclose information under Regulation FD and to provide financial statements and exhibits. This filing indicates that the company is providing information that was not previously public, which could include updates on its business operations or financial performance. For investors, this matters because new disclosures can impact the stock price, especially if the information reveals significant positive or negative developments for the company, BioLargo, Inc. (BLGO).

Why It Matters

This filing signals that BioLargo, Inc. is making new information public, which could influence investor perception and the stock's valuation. Investors should review the full filing for specific details that might affect their investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing and does not inherently present a high risk, but the content of the disclosure could be material.

Analyst Insight

A smart investor would immediately review the full 8-K filing to understand the specific details of the Regulation FD disclosure and the financial statements/exhibits, as this information could be material to BioLargo, Inc.'s (BLGO) valuation and future prospects.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by BioLargo, Inc.?

The primary purpose of this 8-K filing by BioLargo, Inc. is to disclose information under Regulation FD and to provide Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' sections.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 10, 2024, as stated under 'Date of Report (Date of earliest event reported): January 10, 2024'.

What is the trading symbol and exchange for BioLargo, Inc.'s Common Stock?

BioLargo, Inc.'s Common Stock trades under the symbol BLGO on the OTCQB exchange, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.

What is BioLargo, Inc.'s business address?

BioLargo, Inc.'s business address is 14921 Chestnut St., Westminster, California 92683, as detailed in the 'BUSINESS ADDRESS' section of the filing.

Has BioLargo, Inc. operated under different names in the past?

Yes, BioLargo, Inc. has operated under former names including NUWAY MEDICAL INC (changed 20030205), NUWAY ENERGY INC (changed 20010815), and LATIN AMERICAN CASINOS INC (changed 19960520), as listed in the 'FORMER COMPANY' sections.

Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-10 12:12:54

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.   BioLargo, Inc., intends to present the slides attached as Exhibit 99.1 , which are incorporated herein by reference, on January 10, 2024, 9:00 AM Pacific Time, at a webcast investor conference hosted by EmergingGrowth.com.   The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the slide presentation attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in Exhibit 99.1 attached hereto.    

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.   (d)         Exhibits.       Exhibit No. Description 99.1 Slide deck presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)    

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     Date: January 10, 2024 BIOLARGO, INC.         By: /s/ Dennis P. Calvert       Dennis P. Calvert     President and Chief Executive Officer    

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing